Tags

Health

  • Brexit’s Impact on Healthcare and Life Sciences

    Health and life sciences are heavily regulated sectors, which directly employ a significant proportion of the workforce across health and care delivery, pharmaceuticals, research and development, education, animal health and the many other issues covered by the sector. The sector drives a significant percentage of trade inside and outside the EU market and healthcare consumes,…

  • FTI Consulting EU 2016 Outlook

    The EU is going through something of an existential crisis and 2016 will arguably be the most critical year in its history. Challenges range from refugees and migration to the Brexit referendum and growing anti-EU sentiment and populism in many member states. At the same issues like tax, the Digital Single Market, the circular economy…

  • mHealth: Harnessing Growth and Innovation

    mHealth is changing the face of healthcare. While its potential is vast, the test for healthcare systems is to capture this value and translate it into concrete results. In our latest snapshot Kyra Obolensky and Lavinia Trehane from FTI Consulting’s healthcare team identify the challenges of building a robust and secure mHealth ecosystem and explore…

  • HTA cooperation at EU level: From “agreeing on to doing”, from therapeutic added value to cost effectiveness

    The heated debate over price transparency before the Christmas break distracted us from another important development which, being often perceived as too technical and theoretical, may in fact result in significant changes for the pharmaceutical industry: EU level cooperation on Health Technology Assessments (HTA) – the method for assessing the ways science & technology are…

  • Can high-priced medicines constitute an abuse of a dominant position in the EU?

    The price of medicines has inevitably always been, and is likely to remain, a long-standing matter of contention between originator companies, governments and patients. It has however become more acute since the launch of some very innovative but very highly priced medicines in recent months, says FTI Consulting’s Darren Kinsella.   Never mind that these…

Back to top